A Clinical Study of Standard TEMODAL [temozolomide] Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM).

Trial Profile

A Clinical Study of Standard TEMODAL [temozolomide] Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM).

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 May 2013 Primary endpoint 'Overall-survival-duration' has been met.
    • 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top